<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003092</url>
  </required_header>
  <id_info>
    <org_study_id>RX-5902-P1-01</org_study_id>
    <nct_id>NCT02003092</nct_id>
  </id_info>
  <brief_title>RX-5902 Treatment of Subjects With Triple Negative Breast Cancer</brief_title>
  <official_title>A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rexahn Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rexahn Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902&#xD;
      identified in the phase 1 to treat subjects with triple negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this dose-finding, open-label, single-agent study of RX-5902, subjects will be treated for&#xD;
      up to 6 cycles of therapy. RX-5902 will be administered orally daily for 3 weeks followed by&#xD;
      1 week of rest in each cycle. All subjects will be followed for at least 30 days after the&#xD;
      last dose of study agent for safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) (Phase 1)</measure>
    <time_frame>after 4 weeks of treatment with RX-5902</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival rate and/or overall clinical response rate (Phase 2)</measure>
    <time_frame>16 weeks of treatment with RX-5902</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of RX-5902</measure>
    <time_frame>predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8 hrs after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tumor size mm</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (Phase 2)</measure>
    <time_frame>Baseline and at 4, 8, 12, 16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (Phase 2)</measure>
    <time_frame>Baseline and at 4, 8, 12, 16 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>phosphorylated P68 by IHC</measure>
    <time_frame>baseline and 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Tumor burden response (Phase 2)</measure>
    <time_frame>Baseline and at 4, 8, 12, 16 and 24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>RX-5902</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX-5902</intervention_name>
    <description>escalating doses (mg)</description>
    <arm_group_label>RX-5902</arm_group_label>
    <other_name>Supinoxinâ„¢</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female who are 18 yrs or older&#xD;
&#xD;
          -  Histologically confirmed triple negative breast cancer that are refractory,&#xD;
             intolerant, or ineligible to receive approved standard therapies&#xD;
&#xD;
          -  Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST)&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary brain tumor or active brain metastasis&#xD;
&#xD;
          -  Not recovered to less than or equal to Grade 1 toxicities (except Grade 2 alopecia or&#xD;
             neuropathy) associated with previous cancer therapies&#xD;
&#xD;
          -  Any other cancer treatments within 2 weeks of planned study treatment&#xD;
&#xD;
          -  History of any medical or psychiatric condition or addictive disorder, or lab&#xD;
             abnormality that in the opinion of the investigator, may increase risks or may&#xD;
             interfere with study participation or interpretation of study results&#xD;
&#xD;
          -  History of clinically significant GI bleed, intestinal obstruction, or GI perforation&#xD;
             within 6 months of study dose&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  History of long QT syndrome or clinically significant cardiac arrhythmias (except&#xD;
             stable atrial fibrillation)&#xD;
&#xD;
          -  Myocardial infarction within 6 months of study dose&#xD;
&#xD;
          -  Active infection requiring IV antibiotics within 2 weeks of study dose&#xD;
&#xD;
          -  History of Hepatitis B, C, or HIV&#xD;
&#xD;
          -  Use of potent inhibitor or inducer of CYP3A4/3A5 within 14 days of planned study&#xD;
             treatment or expected requirement for use of such a drug during study&#xD;
&#xD;
          -  Use of a potent inhibitor or inducer of drug transporters or conjugating enzymes&#xD;
             within 14 days prior to planned study treatment or expected requirement for use of&#xD;
             such a drug during study&#xD;
&#xD;
          -  Receiving other investigational agents or not yet completed 30 days since completion&#xD;
             of an investigational study&#xD;
&#xD;
          -  Pregnant, planning a pregnancy, or breast feeding&#xD;
&#xD;
          -  Male or female not willing to use adequate contraceptive precautions during the study&#xD;
             period. Females must either be surgically sterile, post-menopausal for 12 months, or&#xD;
             use a contraceptive approved by sponsor.&#xD;
&#xD;
          -  Unwilling or unable to provide written informed consent, comply with study&#xD;
             requirements, or be available for follow-up assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ely Benaim, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rexahn Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rexahn site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rexahn Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rexahn site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rexahn Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rexahn Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rexahn Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rexahn Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rexahn site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic</keyword>
  <keyword>Rexahn</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Triple Negative Breast Cancer</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>June 15, 2020</submitted>
    <returned>July 2, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

